Limits...
BounceBack capsules for reduction of DOMS after eccentric exercise: a randomized, double-blind, placebo-controlled, crossover pilot study.

Udani JK, Singh BB, Singh VJ, Sandoval E - J Int Soc Sports Nutr (2009)

Bottom Line: There were trends towards reductions in plasma indicators of inflammation (high sensitivity C-reactive protein) and muscle damage (creatine phosphokinase and myoglobin).The differences in the serological markers of DOMS, while not statistically significant, appear to support the clinical findings.The product appears to have a good safety profile and further study with a larger sample size is warranted based on the current results.

View Article: PubMed Central - HTML - PubMed

Affiliation: Medicus Research LLC, Northridge, California 91325, USA. jay.udani@medicusresearch.com.

ABSTRACT

Background: Delayed onset muscle soreness (DOMS) is muscle pain and discomfort experienced approximately one to three days after exercise. DOMS is thought to be a result of microscopic muscle fiber tears that occur more commonly after eccentric exercise rather than concentric exercise. This study sought to test the efficacy of a proprietary dietary supplement, BounceBack, to alleviate the severity of DOMS after standardized eccentric exercise.

Methods: The study was a randomized, double-blind, placebo-controlled, crossover study. Ten healthy community-dwelling untrained subjects, ranging in age from 18-45 years, were enrolled. Mean differences within and between groups were assessed inferentially at each data collection time-point using t-tests for all outcome measures.

Results: In this controlled pilot study, intake of BounceBack capsules for 30 days resulted in a significant reduction in standardized measures of pain and tenderness post-eccentric exercise compared to the placebo group. There were trends towards reductions in plasma indicators of inflammation (high sensitivity C-reactive protein) and muscle damage (creatine phosphokinase and myoglobin).

Conclusion: BounceBack capsules were able to significantly reduce standardized measures of pain and tenderness at several post-eccentric exercise time points in comparison to placebo. The differences in the serological markers of DOMS, while not statistically significant, appear to support the clinical findings. The product appears to have a good safety profile and further study with a larger sample size is warranted based on the current results.

No MeSH data available.


Related in: MedlinePlus

Energy expenditure 48 hours before exercise protocol.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2698827&req=5

Figure 4: Energy expenditure 48 hours before exercise protocol.

Mentions: Data analysis from the SenseWear™ Armband revealed that there was no significant difference in Total Energy Expenditure (EE) between the two groups in the 48 hour period prior to exercise. EE was composed of Measured Energy Expenditure plus Offbody Energy Expenditure. The BounceBack™ group demonstrated a greater Measured Energy Expenditure compared to the placebo group: METs (physical activity duration and levels) of 720 ± 1012 (mean ± standard deviation) compared to 460 ± 785 (p = 0.009) (Figure 4). In contrast, the Offbody Energy Expenditure was greater for the placebo group: 661 ± 800 compared to 493 ± 637 (p = 0.009). The BounceBack™ group demonstrated greater Active Energy Expenditure: METs 211 ± 322 compared to 88 ± 173 for the placebo group (p = 0.009) (Figure 3). The Average METs was greater for the BounceBack™ group compared to the placebo group: 1.9 ± 1.5 compared to 1.3 ± 1.0 (p = 0.013).


BounceBack capsules for reduction of DOMS after eccentric exercise: a randomized, double-blind, placebo-controlled, crossover pilot study.

Udani JK, Singh BB, Singh VJ, Sandoval E - J Int Soc Sports Nutr (2009)

Energy expenditure 48 hours before exercise protocol.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2698827&req=5

Figure 4: Energy expenditure 48 hours before exercise protocol.
Mentions: Data analysis from the SenseWear™ Armband revealed that there was no significant difference in Total Energy Expenditure (EE) between the two groups in the 48 hour period prior to exercise. EE was composed of Measured Energy Expenditure plus Offbody Energy Expenditure. The BounceBack™ group demonstrated a greater Measured Energy Expenditure compared to the placebo group: METs (physical activity duration and levels) of 720 ± 1012 (mean ± standard deviation) compared to 460 ± 785 (p = 0.009) (Figure 4). In contrast, the Offbody Energy Expenditure was greater for the placebo group: 661 ± 800 compared to 493 ± 637 (p = 0.009). The BounceBack™ group demonstrated greater Active Energy Expenditure: METs 211 ± 322 compared to 88 ± 173 for the placebo group (p = 0.009) (Figure 3). The Average METs was greater for the BounceBack™ group compared to the placebo group: 1.9 ± 1.5 compared to 1.3 ± 1.0 (p = 0.013).

Bottom Line: There were trends towards reductions in plasma indicators of inflammation (high sensitivity C-reactive protein) and muscle damage (creatine phosphokinase and myoglobin).The differences in the serological markers of DOMS, while not statistically significant, appear to support the clinical findings.The product appears to have a good safety profile and further study with a larger sample size is warranted based on the current results.

View Article: PubMed Central - HTML - PubMed

Affiliation: Medicus Research LLC, Northridge, California 91325, USA. jay.udani@medicusresearch.com.

ABSTRACT

Background: Delayed onset muscle soreness (DOMS) is muscle pain and discomfort experienced approximately one to three days after exercise. DOMS is thought to be a result of microscopic muscle fiber tears that occur more commonly after eccentric exercise rather than concentric exercise. This study sought to test the efficacy of a proprietary dietary supplement, BounceBack, to alleviate the severity of DOMS after standardized eccentric exercise.

Methods: The study was a randomized, double-blind, placebo-controlled, crossover study. Ten healthy community-dwelling untrained subjects, ranging in age from 18-45 years, were enrolled. Mean differences within and between groups were assessed inferentially at each data collection time-point using t-tests for all outcome measures.

Results: In this controlled pilot study, intake of BounceBack capsules for 30 days resulted in a significant reduction in standardized measures of pain and tenderness post-eccentric exercise compared to the placebo group. There were trends towards reductions in plasma indicators of inflammation (high sensitivity C-reactive protein) and muscle damage (creatine phosphokinase and myoglobin).

Conclusion: BounceBack capsules were able to significantly reduce standardized measures of pain and tenderness at several post-eccentric exercise time points in comparison to placebo. The differences in the serological markers of DOMS, while not statistically significant, appear to support the clinical findings. The product appears to have a good safety profile and further study with a larger sample size is warranted based on the current results.

No MeSH data available.


Related in: MedlinePlus